CSTL
Bearish signalScored 2026-10-25 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Castle Biosciences, Inc.
- Nom
- Castle Biosciences, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Diagnostics & Research
- Bourse
- NASDAQ
- Capitalisation
- $1.0B
- Employés
- 1,002
- PDG
- Derek J. Maetzold
- Site web
- https://castlebiosciences.com
- Marché
- BDSXBIAFFRNMGHMDXHMYGN
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 34 324 titres (~1 156 797,80 $ US)
- Insiders
- MAETZOLD DEREK J
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$4,446,004
Avg sell (VWAP, 90d window) $32.40 vs last close $33.30 (+2.8%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$2,838,198 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-19
- Liquidity
- Thin $11,367,834/day · 20d vol
- Last synced
-
2026-10-26 21:10:20
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-19 | MAETZOLD DEREK J | Sell · S | 8,580 | $31.91 | $273,788 | Form 4 |
| 2026-10-12 | Juvenal Tobin W | Sell · S · 10b5-1 | 3,288 | $33.64 | $110,608 | Form 4 |
| 2026-10-05 | MAETZOLD DEREK J | Sell · S · 10b5-1 | 8,580 | $35.57 | $305,156 | Form 4 |
| 2026-10-01 | Oelschlager Kristen M | Sell · S · 10b5-1 | 1,346 | $36.38 | $48,967 | Form 4 |
| 2026-09-30 | Juvenal Tobin W | Sell · S · 10b5-1 | 1,034 | $34.20 | $35,363 | Form 4 |
| 2026-09-29 | Juvenal Tobin W | Sell · S · 10b5-1 | 5,543 | $35.50 | $196,765 | Form 4 |
| 2026-09-21 | MAETZOLD DEREK J | Sell · S · 10b5-1 | 8,580 | $35.33 | $303,166 | Form 4 |
| 2026-09-15 | Juvenal Tobin W | Sell · S · 10b5-1 | 3,294 | $35.14 | $115,758 | Form 4 |
| 2026-09-14 | Juvenal Tobin W | Sell · S · 10b5-1 | 3,306 | $32.32 | $106,863 | Form 4 |
| 2026-09-11 | MAETZOLD DEREK J | Sell · S · 10b5-1 | 223 | $32.78 | $7,310 | Form 4 |
| 2026-09-01 | Oelschlager Kristen M | Sell · S · 10b5-1 | 200 | $34.02 | $6,804 | Form 4 |
| 2026-08-31 | Juvenal Tobin W | Sell · S · 10b5-1 | 1,730 | $32.81 | $56,761 | Form 4 |
| 2026-08-28 | MAETZOLD DEREK J | Sell · S · 10b5-1 | 956 | $33.88 | $32,389 | Form 4 |
| 2026-08-25 | Juvenal Tobin W | Sell · S · 10b5-1 | 9,050 | $35.04 | $317,112 | Form 4 |
| 2026-08-25 | Oelschlager Kristen M | Sell · S | 5,223 | $34.64 | $180,919 | Form 4 |
| 2026-08-24 | Oelschlager Kristen M | Sell · S | 12,218 | $33.69 | $411,588 | Form 4 |
| 2026-08-17 | Juvenal Tobin W | Sell · S · 10b5-1 | 1,730 | $29.59 | $51,191 | Form 4 |
| 2026-08-14 | MAETZOLD DEREK J | Sell · S · 10b5-1 | 1,100 | $30.02 | $33,022 | Form 4 |
| 2026-08-14 | Stokes Frank | Sell · S | 24,908 | $29.77 | $741,511 | Form 4 |
| 2026-08-05 | MAETZOLD DEREK J | Sell · S · 10b5-1 | 2,546 | $30.68 | $78,114 | Form 4 |
| 2026-08-04 | MAETZOLD DEREK J | Sell · S · 10b5-1 | 11,935 | $31.34 | $373,995 | Form 4 |
| 2026-08-03 | Oelschlager Kristen M | Sell · S · 10b5-1 | 1,100 | $30.62 | $33,682 | Form 4 |
| 2026-08-03 | Juvenal Tobin W | Sell · S · 10b5-1 | 1,730 | $28.25 | $48,872 | Form 4 |
| 2026-08-03 | MAETZOLD DEREK J | Sell · S · 10b5-1 | 10,664 | $30.35 | $323,684 | Form 4 |
| 2026-07-31 | Juvenal Tobin W | Sell · S · 10b5-1 | 1,891 | $30.26 | $57,229 | Form 4 |
| 2026-07-31 | MAETZOLD DEREK J | Sell · S · 10b5-1 | 6,480 | $30.15 | $195,385 | Form 4 |
| 2026-07-27 | MAETZOLD DEREK J | Sell · S · 10b5-1 | 232 | $25.06 | $5,814 | Form 4 |
| 2025-11-24 | Juvenal Tobin W | Sell · S · 10b5-1 | 1,301 | $38.39 | $49,945 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-03-15 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-12-23 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-12-21 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-10-25 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
CSTL combines a weak catalyst score (25) driven by heavy insider selling and no actionable event trigger with deteriorating fundamentals — a return to net losses in 2025 and negative EPS undermine the strong balance…
The first sentence of the analysis written for CSTL on 2026-10-25 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 5.26 · operating margin -12% — readings disagree
Suggested stop 30.74, nearest stored support minus 0.5 ATR(7.7% under the last close). Reward/risk to the next stored resistance is 1.83. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-15 Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026 FRIENDSWOOD, Texas, Oct. 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2026, after the close of market on Thursday, Nov. 5, 2026.
- 2026-10-12 Castle Biosciences Inc (CSTL) Shares Fall 4.8% -- What GF Score of 80 Tells Investors Castle Biosciences Valuation AssessmentOn October 12, 2026, Castle Biosciences Inc (CSTL) shares fell 4.8% to $32.76, marking a significant decline in the conte
- 2026-10-12 ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett''s Esophagus Studies highlight how molecular risk assessment with TissueCypher can help inform surveillance and treatment decisions beyond biopsy findings alone FRIENDSWOOD, Texas, Oct. 12, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data from three studies evaluating its TissueCypher Barrett''s Esophagus (BE) test will be presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting and Postgraduate Course, taking place Oct. 9-14 in Nashville, Tennessee. The studies include two case reports and one multi-center study highlighting how TissueCypher can provide additional risk information beyond histopathology to support risk-aligned patient management decisions.
- 2026-10-06 Castle Biosciences (NASDAQ:CSTL) Stock Price Down 6.1% Following Insider Selling Shares of Castle Biosciences, Inc. (NASDAQ: CSTL - Get Free Report) fell 6.1% during mid-day trading on Tuesday after an insider sold shares in the company. The stock traded as low as $34.48 and last traded at $34.4220. Approximately 69,597 shares changed hands during trading, a decline of 82% from the average daily volume of 395,572
- 2026-10-02 Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 1,034 Shares of Stock Castle Biosciences, Inc. (NASDAQ: CSTL - Get Free Report) insider Tobin Juvenal sold 1,034 shares of the company''s stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $34.20, for a total value of $35,362.80. Following the transaction, the insider directly owned 52,007 shares of the company''s
- 2026-09-30 Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management Data show patients with low-risk DecisionDx-Melanoma i31-SLNB results had sentinel lymph node (SLN) positivity below 5% when biopsied, and eligible patients who avoided SLNB had five-year recurrence-free survival (RFS) of 99.6% Separate ePoster shows DecisionDx-Melanoma identifies early-stage, transected melanomas with recurrence risk similar to that seen in stage IIB disease, supporting closer surveillance when staging is uncertain FRIENDSWOOD, Texas, Sept. 30, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data on DecisionDx-Melanoma at the European Academy of Dermatology and Venereology (EADV) Congress 2026, taking place Sept.
- 2026-09-28 New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett''s Esophagus FRIENDSWOOD, Texas, Sept. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study showing that its TissueCypher® Barrett''s Esophagus Test helped guide risk-aligned management decisions for patients with non-dysplastic Barrett''s esophagus (NDBE).
- 2026-09-24 New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™ Study data showed more than half of patients who used targeted systemic therapies modified treatment due to lack of efficacy Among patients surveyed in the study, 94% of those open to a new systemic therapy expressed interest in molecular testing to help identify a more effective treatment FRIENDSWOOD, Texas, Sept. 24, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new study highlighting the challenges patients with atopic dermatitis (AD) experience in achieving their treatment goals and strong patient interest in molecular testing to help guide systemic therapy selection.
- 2026-09-22 Castle Biosciences to Open New Laboratory Facility in Scottsdale New 55,000-square-foot facility expands Castle''s operational footprint in Arizona to support growing test volumes and long-term growth FRIENDSWOOD, Texas, Sept. 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the opening of its new laboratory and office facility in Scottsdale, Arizona.
- 2026-09-15 New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett''s Esophagus Decision modeling study shows use of TissueCypher can nearly double appropriate escalation of care for patients with non-dysplastic Barrett''s esophagus who later progress to cancer, while substantially reducing overuse of procedures in patients who do not progress FRIENDSWOOD, Texas, Sept. 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new decision modeling study showing that the TissueCypher® Barrett''s Esophagus test (TSP-9) can help better align Barrett''s esophagus (BE) management with a patient''s individual risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC).
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 79.4% | 81.9% | 79.5% | 76.6% | 83.2% | |
| Ebit Margin | -8.5% | 6.7% | -26.1% | -50.3% | -42.5% | |
| Ebitda Margin | 3.3% | 11.5% | -20.5% | -42.6% | -38.9% | |
| Operating Profit Margin | -12.4% | 2.6% | -30.9% | -53.2% | -42.6% | |
| Pretax Profit Margin | -8.6% | 6.5% | -26.1% | -50.3% | -42.5% | |
| Continuous Operations Profit Margin | -7.0% | 5.5% | -26.1% | -49.0% | -33.3% | |
| Net Profit Margin | -7.0% | 5.5% | -26.1% | -49.0% | -33.3% | |
| Bottom Line Profit Margin | -7.0% | 5.5% | -26.1% | -49.0% | -33.3% | |
| Current Ratio | 5.258 | 7.292 | 6.202 | 8.090 | 14.215 | |
| Quick Ratio | 5.109 | 7.127 | 6.035 | 7.980 | 14.133 | |
| Solvency Ratio | 0.154 | 0.454 | -0.727 | -1.175 | -0.549 | |
| Cash Ratio | 1.700 | 2.424 | 2.074 | 3.403 | 13.246 | |
| Price To Earnings Ratio | -46.867 | 40.379 | -10.084 | -9.124 | -34.573 | |
| Price To Earnings Growth Ratio | 0.208 | -0.309 | 0.591 | -0.084 | -0.267 | |
| Forward Price To Earnings Growth Ratio | 0.208 | -0.309 | 0.591 | -0.084 | -0.267 | |
| Price To Earnings Diluted Ratio | -46.867 | 42.984 | -10.084 | -9.124 | -34.573 | |
| Price To Earnings Diluted Growth Ratio | 0.200 | -0.333 | 0.591 | -0.084 | -0.267 | |
| Price To Book Ratio | 2.395 | 1.624 | 1.478 | 1.537 | 2.617 | |
| Price To Sales Ratio | 3.276 | 2.229 | 2.632 | 4.475 | 11.454 | |
| Price To Free Cash Flow Ratio | 39.806 | 20.258 | -30.051 | -12.970 | -47.967 | |
| Price To Operating Cash Flow Ratio | 17.523 | 11.412 | -102.806 | -14.724 | -56.768 | |
| Debt To Assets Ratio | 0.064 | 0.050 | 0.034 | 0.030 | 0.018 | |
| Debt To Equity Ratio | 0.078 | 0.058 | 0.039 | 0.034 | 0.020 | |
| Debt To Capital Ratio | 0.073 | 0.055 | 0.038 | 0.032 | 0.020 | |
| Long Term Debt To Capital Ratio | 0.020 | 0.021 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.229 | 1.165 | 1.159 | 1.121 | 1.123 | |
| Working Capital Turnover Ratio | 1.141 | 1.189 | 0.872 | 0.468 | 0.255 | |
| Operating Cash Flow Ratio | 0.937 | 1.313 | -0.118 | -1.153 | -0.763 | |
| Operating Cash Flow Sales Ratio | 0.187 | 0.195 | -0.026 | -0.304 | -0.202 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.440 | 0.563 | 3.421 | 1.135 | 1.183 | |
| Debt Service Coverage Ratio | 33.199 | 40.724 | -4,102.273 | -3,328.118 | -27,884.000 | |
| Interest Coverage Ratio | -497.791 | 15.026 | -6,179.727 | -4,285.588 | -40,079.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 154.309 | 233.331 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 1.743 | 2.462 | -0.367 | -3.109 | -2.314 | |
| Capital Expenditure Coverage Ratio | 1.786 | 2.290 | -0.413 | -7.396 | -5.450 | |
| Dividend Paid And Capex Coverage Ratio | 1.786 | 2.290 | -0.413 | -7.396 | -5.450 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 92.369 | 16.961 | -10.991 | -8.634 | -20.659 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 79.4% | ▼-2.5% | ▼-0.8% |
| Ebit Margin | -8.6% | ▼-15.2% | ▲15.6% |
| Ebitda Margin | 3.3% | ▼-8.2% | ▲20.7% |
| Operating Profit Margin | -12.4% | ▼-15.0% | ▲14.9% |
| Pretax Profit Margin | -8.6% | ▼-15.1% | ▲15.6% |
| Continuous Operations Profit Margin | -7.0% | ▼-12.5% | ▲15.0% |
| Net Profit Margin | -7.0% | ▼-12.5% | ▲15.0% |
| Bottom Line Profit Margin | -7.0% | ▼-12.5% | ▲15.0% |
| Current Ratio | 5.258 | ▼-2.034 | ▼-2.953 |
| Quick Ratio | 5.109 | ▼-2.018 | ▼-2.968 |
| Solvency Ratio | 0.154 | ▼-0.300 | ▲0.523 |
| Cash Ratio | 1.700 | ▼-0.724 | ▼-2.869 |
| Price To Earnings Ratio | -46.867 | ▼-87.246 | ▼-34.814 |
| Price To Earnings Growth Ratio | 0.208 | ▲0.516 | ▲0.180 |
| Forward Price To Earnings Growth Ratio | 0.208 | ▲0.516 | ▲0.180 |
| Price To Earnings Diluted Ratio | -46.867 | ▼-89.851 | ▼-35.335 |
| Price To Earnings Diluted Growth Ratio | 0.200 | ▲0.534 | ▲0.179 |
| Price To Book Ratio | 2.395 | ▲0.771 | ▲0.465 |
| Price To Sales Ratio | 3.276 | ▲1.046 | ▼-1.538 |
| Price To Free Cash Flow Ratio | 39.806 | ▲19.548 | ▲45.991 |
| Price To Operating Cash Flow Ratio | 17.523 | ▲6.111 | ▲46.596 |
| Debt To Assets Ratio | 0.064 | ▲0.014 | ▲0.025 |
| Debt To Equity Ratio | 0.078 | ▲0.021 | ▲0.033 |
| Debt To Capital Ratio | 0.073 | ▲0.018 | ▲0.029 |
| Long Term Debt To Capital Ratio | 0.020 | ▼-0.001 | ▲0.012 |
| Financial Leverage Ratio | 1.229 | ▲0.063 | ▲0.069 |
| Working Capital Turnover Ratio | 1.141 | ▼-0.047 | ▲0.356 |
| Operating Cash Flow Ratio | 0.937 | ▼-0.376 | ▲0.894 |
| Operating Cash Flow Sales Ratio | 0.187 | ▼-0.008 | ▲0.217 |
| Free Cash Flow Operating Cash Flow Ratio | 0.440 | ▼-0.123 | ▼-0.908 |
| Debt Service Coverage Ratio | 33.199 | ▼-7.525 | ▲7081.292 |
| Interest Coverage Ratio | -497.791 | ▼-512.817 | ▲9707.625 |
| Short Term Operating Cash Flow Coverage Ratio | 154.309 | ▼-79.022 | ▲76.781 |
| Operating Cash Flow Coverage Ratio | 1.743 | ▼-0.719 | ▲2.060 |
| Capital Expenditure Coverage Ratio | 1.786 | ▼-0.504 | ▲3.623 |
| Dividend Paid And Capex Coverage Ratio | 1.786 | ▼-0.504 | ▲3.623 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 92.369 | ▲75.408 | ▲78.560 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.13B | $740.2M | $578.4M | $613.3M | $1.08B | |
| Enterprise value | $1.05B | $646.9M | $494.9M | $503.8M | $756.2M | |
| EV / Sales | 3.04x | 1.95x | 2.25x | 3.68x | 8.04x | |
| EV / Op. cash flow | 16.28x | 9.97x | -87.96x | -12.09x | -39.84x | |
| EV / Free cash flow | 36.99x | 17.70x | -25.71x | -10.65x | -33.66x | |
| EV / EBITDA | 92.37x | 16.96x | -10.99x | -8.63x | -20.66x | |
| Net debt / EBITDA | -7.04x | -2.45x | 1.85x | 1.88x | 8.78x | |
| Current ratio | 5.26x | 7.29x | 6.20x | 8.09x | 14.21x | |
| Income quality | -2.66x | 3.56x | 0.10x | 0.62x | 0.61x | |
| Graham number | — | $16 | — | — | — | |
| Graham net-net | $8 | $9 | $8 | $9 | $12 | |
| Tax burden | 81.9% | 84.6% | 100.2% | 97.4% | 78.2% | |
| Interest burden | 100.3% | 97.4% | 100.0% | 100.0% | 100.0% | |
| Working capital | $292.4M | $310.8M | $248.0M | $256.2M | $328.9M | |
| Invested capital | $504.2M | $479.7M | $403.0M | $409.0M | $434.7M | |
| Return on assets | -4.2% | 3.4% | -12.7% | -15.0% | -6.8% | |
| Operating ROA | -7.7% | 1.8% | -15.1% | -16.0% | -8.9% | |
| Return on tangible assets | -5.0% | 4.3% | -17.1% | -20.9% | -8.4% | |
| Return on equity | -5.1% | 4.0% | -14.7% | -16.8% | -7.6% | |
| Return on invested capital | -6.8% | 1.5% | -16.7% | -17.2% | -7.1% | |
| Return on capital employed | -8.4% | 1.8% | -16.8% | -17.7% | -9.2% | |
| Earnings yield | -2.1% | 2.5% | -9.9% | -10.9% | -2.9% | |
| Free cash flow yield | 2.5% | 4.9% | -3.3% | -7.7% | -2.1% | |
| Capex / Op. cash flow | 56.0% | 43.7% | -242.1% | -13.5% | -18.3% | |
| Capex / Depreciation | 88.3% | 177.1% | 110.5% | 53.4% | 102.2% | |
| Capex / Sales | 10.5% | 8.5% | 6.2% | 4.1% | 3.7% | |
| SG&A / Sales | 66.6% | 60.2% | 82.0% | 104.4% | 92.2% | |
| R&D / Sales | 15.1% | 15.7% | 24.4% | 32.8% | 31.5% | |
| Stock comp / Sales | 13.3% | 15.2% | 23.3% | 26.5% | 23.1% | |
| Intangibles / Total assets | 17.2% | 20.0% | 25.9% | 28.2% | 19.2% | |
| Days sales outstanding | 46d | 56d | 64d | 63d | 67d | |
| Days payables outstanding | 96d | 42d | 83d | 54d | 59d | |
| Operating cycle | 99d | 106d | 128d | 108d | 114d | |
| Cash conversion cycle | 3d | 64d | 45d | 54d | 55d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years